Open an account

Structure Therapeutics

GPCR · NASDAQ

$22.88+$0.87 (+3.95%)TodayMarket closed ·
Prev close $22.01

About GPCR

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California and currently employs 220 full-time employees. The company went IPO on 2023-02-03. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. The company is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. The company is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.

Employees
220
Headquarters
South San Francisco, California
Listed
Feb 3, 2023
Sector
Health Care
Industry
Pharmaceuticals
Website
structuretx.com

GPCR key statistics

Market cap
1.50B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.49M
Volume
1.14M
Open price
$22.11
High today
$23.83
Low today
$22.11
52 Week high
$94.90
52 Week low
$20.73

Structure Therapeutics (GPCR) at a glance

As of Oct 20, 2026, Structure Therapeutics (GPCR) shares are priced at $22.88, giving the company a market cap of 1.50B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $22.11 and $23.83. The current price is 3.5% above the day's low and 4.0% below its high.

Volume so far is 1.14M shares, below the average of 1.49M shares a day.

Over the past year Structure Therapeutics has ranged from $20.73 to $94.90, and now sits 3% of the way up that range.

Structure Therapeutics met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q2 FY26 it reported -$0.49 per share against an estimate of -$0.4056.

The average analyst price target is $109.36, 378.0% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 10 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 17 analystsAvg $109.36
Low
$70.70
Now
$22.88
High
$152.25

GPCR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 1.2% on average.

  1. Q3 FY24: reported -$0.60 per share against an estimate of -$0.1896
  2. Q4 FY24: reported -$0.69 per share against an estimate of -$0.2283
  3. Q1 FY25: reported -$0.81 per share against an estimate of -$0.2335
  4. Q2 FY25: reported -$1.08 per share against an estimate of -$0.2813
  5. Q3 FY25: reported -$1.11 per share against an estimate of -$0.3584
  6. Q4 FY25: reported -$1.22 per share against an estimate of -$0.4746
  7. Q1 FY26: reported -$0.35 per share against an estimate of -$0.3543
  8. Q2 FY26: reported -$0.49 per share against an estimate of -$0.4056

GPCR news

  • Vandana Singh

    Structure Therapeutics Advances Weight-Loss Pills With New Clinical Data

  • Stjepan Kalinic

    Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model

  • Vandana Singh

    What's Going On With Structure Therapeutics Stock On Wednesday?

  • Vandana Singh

    Structure Therapeutics Stock Explodes As Much-Awaited Experimental Oral Drug Trial Shows Weight Loss Of 16%

  • Vandana Singh

    Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It

  • Vandana Singh

    Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments

  • Structure Therapeutics CEO Expects Pills To Capture 25% To 50% Of GLP-1 Weight-Loss Market By 2030; Says Strategic Partner For Commercialization Of Its Medicine Needs To Have Strong Relationships With Primary Care Doctors

  • 10 Health Care Stocks Whale Activity In Today's Session

Similar companies

Companies in the same industry as Structure Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.